Castle Biosciences to Participate in Upcoming Investor Conferences
Castle Biosciences (Nasdaq: CSTL), a healthcare diagnostics company, announced its participation in three upcoming investor conferences in September 2025. The company will present at Baird's 2025 Global Healthcare Conference on September 10 at 10:15 a.m. Eastern time, with a live webcast available on their investor relations website.
Additionally, Castle's management will be available for one-on-one meetings during the Wells Fargo Healthcare Conference on September 4 and the Lake Street Best Ideas Growth Conference on September 11. Meeting requests must be coordinated through Wells Fargo and Lake Street Capital Markets.
Castle Biosciences (Nasdaq: CSTL), azienda nel settore diagnostico sanitario, ha annunciato la sua partecipazione a tre conferenze per investitori previste a settembre 2025. La società terrà una presentazione al Baird's 2025 Global Healthcare Conference il 10 settembre alle 10:15 ora Eastern; la diretta streaming sarà disponibile sul sito investor relations.
Inoltre, il management di Castle sarà disponibile per incontri one-to-one durante il Wells Fargo Healthcare Conference il 4 settembre e il Lake Street Best Ideas Growth Conference l'11 settembre. Le richieste di meeting devono essere coordinate tramite Wells Fargo e Lake Street Capital Markets.
Castle Biosciences (Nasdaq: CSTL), una compañía de diagnóstico sanitario, anunció su participación en tres conferencias para inversores en septiembre de 2025. La empresa ofrecerá una presentación en el Baird's 2025 Global Healthcare Conference el 10 de septiembre a las 10:15 a.m. hora Eastern; habrá una retransmisión en directo en su web de relaciones con inversores.
Además, la dirección de Castle estará disponible para reuniones individuales durante el Wells Fargo Healthcare Conference el 4 de septiembre y el Lake Street Best Ideas Growth Conference el 11 de septiembre. Las solicitudes de reunión deben coordinarse a través de Wells Fargo y Lake Street Capital Markets.
Castle Biosciences (Nasdaq: CSTL)는 의료 진단 회사로서 2025년 9월에 예정된 세 곳의 투자자 컨퍼런스에 참여한다고 발표했습니다. 회사는 Baird's 2025 Global Healthcare Conference에서 9월 10일 동부시간(Eastern) 오전 10시 15분에 프레젠테이션을 진행하며, 투자자 관계 웹사이트를 통해 생중계됩니다.
또한 Castle 경영진은 9월 4일 Wells Fargo Healthcare Conference와 9월 11일 Lake Street Best Ideas Growth Conference 기간 중 1:1 미팅에 응할 예정입니다. 미팅 요청은 Wells Fargo와 Lake Street Capital Markets를 통해 조율해야 합니다.
Castle Biosciences (Nasdaq: CSTL), une entreprise de diagnostics de santé, a annoncé sa participation à trois conférences investisseurs en septembre 2025. La société présentera au Baird's 2025 Global Healthcare Conference le 10 septembre à 10h15, heure Eastern ; une diffusion en direct sera disponible sur son site relations investisseurs.
Par ailleurs, la direction de Castle sera disponible pour des rencontres individuelles lors du Wells Fargo Healthcare Conference le 4 septembre et du Lake Street Best Ideas Growth Conference le 11 septembre. Les demandes de rendez-vous doivent être coordonnées via Wells Fargo et Lake Street Capital Markets.
Castle Biosciences (Nasdaq: CSTL), ein Unternehmen im Bereich Diagnostik im Gesundheitswesen, gab seine Teilnahme an drei Investorenkonferenzen im September 2025 bekannt. Das Unternehmen wird am Baird's 2025 Global Healthcare Conference am 10. September um 10:15 Uhr Eastern eine Präsentation halten; ein Live-Webcast ist auf der Investor-Relations-Website verfügbar.
Außerdem steht das Management von Castle für Einzelgespräche beim Wells Fargo Healthcare Conference am 4. September und beim Lake Street Best Ideas Growth Conference am 11. September zur Verfügung. Meeting-Anfragen müssen über Wells Fargo und Lake Street Capital Markets koordiniert werden.
- None.
- None.
FRIENDSWOOD, Texas, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at Baird’s 2025 Global Healthcare Conference on Wednesday, Sept. 10, 2025, at 10:15 a.m. Eastern time.
A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at ir.castlebiosciences.com/events-presentations/. A replay of the webcast will be available following the conclusion of the live broadcast.
Castle will also be available for one-on-one investor meetings during the Wells Fargo 20th Annual Healthcare Conference on Sept. 4, 2025, and the 9th Annual Lake Street Best Ideas Growth (BIG9) Conference on Sept. 11, 2025. Meetings may be requested exclusively through Wells Fargo and Lake Street Capital Markets.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
FAQ
When is Castle Biosciences (CSTL) presenting at Baird's 2025 Global Healthcare Conference?
How can investors access Castle Biosciences' (CSTL) presentation at the Baird conference?
Which investor conferences will Castle Biosciences (CSTL) attend in September 2025?
How can investors schedule one-on-one meetings with Castle Biosciences (CSTL) management?
